Relay Therapeutics RLAY 深 滬
已收盤 08-22 16:00:00 美东时间
3.69
+0.280
+8.21%
華盛通- 最 高3.72
- 今 開3.45
- 成交量 110.92万股
- 最 低 3.4274
- 昨 收 3.41
- 總市值 6.31亿
- 52周最高 10.72
- 市盈率 靜 --
- 換手率 0.65%
- 52周最低 1.775
- 委 比 4.24%
- 總股本 1.71亿
- 歷史最高 64.37
- 量 比 0.95
- 振 幅 8.58%
- 歷史最低 1.775
- 每 手 1
- 風險率 1.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
RLAY stock has given up its prior gain. Relay Therapeutics shares were trading higher after the company reported better-than-expected Q2 financial results.
RLAY stock has given up its prior gain. Relay Therapeutics shares were trading ...
08-08 06:51
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Preview: Relay Therapeutics's Earnings
Relay Therapeutics (NASDAQ:RLAY) is preparing to release its quarterly earnings...
08-07 02:09
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
Relay Therapeutics, a clinical-stage precision medicine company combining cutting-edge computational and experimental technologies, will release its second quarter 2025 financial results and corporate updates after U.S. markets close on August 7, 2025. The company, leveraging its Dynamo® platform to target previously intractable protein targets, focuses on small molecule drug discovery in oncology and genetic diseases.
07-31 20:05
reAlpha Tech Corp. Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
reAlpha Tech Corp. announced the purchase and sale of 14,285,718 shares of its common stock at $0.35 per share in a registered direct offering under Nasdaq rules. Concurrently, the company will issue unregistered warrants for up to 14,285,718 shares with an exercise price of $0.35 per share, exercisable immediately and expiring in five years. The offering is expected to close on July 22, 2025, subject to customary closing conditions. H.C. Wainwri...
07-21 20:30
reAlpha Enhances Mortgage Operations with AI-Powered Loan Officer Assistant
<p>reAlpha Tech Corp. 推出了AI-powered Internal Loan Officer Assistant，旨在提升抵押贷款处理的效率和准确性。该工具已将手动文档准备时间减少60%，并自动化了三分之一的贷款申请流程。公司CEO Jamie Cavanaugh表示，AI工具不是替代人员，而是帮助专业人士更专注于客户服务。行业数据显示，AI技术可将贷款产量提升50%，缩短审批时间，并降低成本30-50%。reAlpha计划继续扩展AI工具以处理更复杂的抵押贷款场景。</p>
07-02 22:00
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
Relay Therapeutics announced the appointment of Dr. Claire Mazumdar to its Board of Directors. Dr. Mazumdar, a seasoned executive with expertise in clinical-stage oncology, joins as Relay prepares to initiate its Phase 3 ReDiscover-2 breast cancer trial. Previously, she was CEO of Bicara Therapeutics and held leadership roles at Rheos Medicines and Third Rock Ventures. Relay Therapeutics specializes in precision medicine, leveraging advanced comp...
06-11 20:05
